Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CytomX Therapeutics, Inc. CTMX

Healthcare  —  Biotechnology
2.70 (0.05) (1.82%) as of 25 Sep
Market cap
$599.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio 0.00 0.00 0.00 8.00

+8 more quarters
P/S ratio 44.86 23.44 7.71 4.63
P/FCF ratio 0.00 0.00 0.00 0.00
P/Operating CF (45.44) (32.61) (25.28) (33.85)
P/B ratio 2.72 2.60 5.93 4.90
Price to Tangible BV 2.73 2.62 6.02 4.97
EV/Sales 27.01 13.82 5.97 3.41
EV/EBITDA 0.00 0.00 0.00 17.41
EV/Operating CF (6.00) (6.13) (6.02) (5.36)
EV/FCF (5.98) (6.11) (6.00) (5.35)
Quick Ratio 9.25 10.21 2.98 3.54
Current Ratio 9.36 10.38 3.09 3.64
Net Debt/EBITDA 13.16 17.21 4.87 8.83
Debt/Assets 0.00% 0.00% 0.00% 0.00%
Debt/Equity 0.00 0.00 0.00 0.00
Asset Turnover 0.07 0.16 0.56 0.76
Operating CF/Net income 0.87 1.40 0.79 1.09
Capex/Depreciation 0.00 0.00 0.96 (0.25)
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 1,241.04% 187.54% 3,202.71% 256.65%
Selling, General and Administrative Expense of Revenue 536.04% 104.23% 1,110.11% 107.78%
Intangible Assets out of Total Assets 0.00 0.00 0.01 0.01
Share Based Compensation of Revenue 181.73% 45.88% 223.08% 23.21%
Graham Net Nets 0.36 0.38 0.16 0.19
Graham Number 0.00 0.00 0.00 2.42
Earnings Yield (13.33%) (8.75%) (0.97%) 12.50%
Free Cash Flow Yield (10.06%) (9.64%) (12.90%) (13.75%)
Revenue per Share 0.01 0.06 0.00 0.04
Operating CF per Share (0.08) (0.14) (0.17) (0.09)
Capex per Share 0.00 0.00 0.00 0.00
Free Cash Flow per Share (0.08) (0.14) (0.17) (0.09)
Cash per Share 1.51 1.96 0.99 0.87
Shareholders Equity per Share 1.38 1.80 0.72 0.65
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 1.38 1.80 0.72 0.65
Free Cash Flow (18.07) (25.55) (23.44) (15.42)
Working Capital 333.29 319.07 97.31 108.19
Capital Expenditures — — (0.20) 0.13
Net Current Asset Value 294.00 313.68 91.36 98.35
EV/EBIT 0.00 0.00 0.00 16.66
Capex to Sales 0.00 0.00 0.30 (0.02)
Net Profit Margin (1,457.40%) (177.89%) (4,451.28%) (238.62%)
Price to Operating Income 0.00 0.00 0.00 22.64
Other line items
Average Receivables 19.68 1.30 2.56 2.49
Average Payables 1.08 0.82 1.19 1.03
Average Assets 278.14 228.93 136.05 148.62
Average Common Equity 210.99 172.50 49.28 41.97

Fold the line items

Columns are period end dates